乌龙制药 URGN 深 沪
等待开盘 08-25 09:30:00 美东时间
46.16
-0.700
-1.49%
华盛通- 最 高47.05
- 今 开46.52
- 成交量 84.97万股
- 最 低 45.27
- 昨 收 46.86
- 总市值 22.56亿
- 52周最高 50.81
- 市盈率 静 --
- 换手率 1.74%
- 52周最低 15.86
- 委 比 60.26%
- 总股本 4888.06万
- 历史最高 69.568
- 量 比 0.67
- 振 幅 3.80%
- 历史最低 3.42
- 每 手 1
- 风险率 8.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UroGen Pharma Announces Strategic Option And Research License Agreement And Related Equity Investment Agreement With IntraGel Therapeutics
Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head ...
08-20 19:02
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
UroGen Pharma announced the submission of an NDA to the FDA for UGN-103, a next-generation mitomycin formulation for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UGN-103 builds on ZUSDURI, the first FDA-approved treatment for this indication, with improvements in manufacturing, reconstitution, and shelf-life. The submission is supported by Phase 3 UTOPIA trial data showing a 77.8% three-month co...
08-17 12:00
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58
Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.
08-06 21:48
UroGen Pharma shares are trading higher after the company reported better-than-expected Q2 financial results.
UroGen Pharma shares are trading higher after the company reported better-than-expected Q2 financial results.
08-05 21:08
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
UroGen Pharma Ltd. (Nasdaq: URGN) announced it will report its second quarter 2026 financial results on August 5, 2026, followed by a live audio webcast and conference call at 10:00 AM ET. The webcast will be available on UroGen’s Investor Relations website, with a replay accessible for 30 days. UroGen is a biotech company focused on developing innovative treatments for urothelial and specialty cancers using its proprietary RTGel® technology, whi...
07-29 12:00
Biotech stocks lead healthcare's overbought list as earnings picks up
Healthcare stocks are in focus as second-quarter earnings season shifts into high gear, with investors evaluating whether recent rallies across biotech, medical technology and healthcare services can ...
07-23 19:18
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
美股大行评级 | 阿斯麦、贝莱德、纽约梅隆银行、信达思、JB亨特运输服务、美国制商银行、PNC金融服务集团等获多家大行集体上调目标价
今日重点评级关注：瑞杰金融：维持Electrovaya"强力买入"评级，目标价从14美元升至22美元；BTIG：维持vTv Therapeutics"买入"评级，目标价从49美元升至57美元
07-17 11:35
UroGen Receives USPTO Notice Of Allowance For Patent Covering Treatment Of Recurrent LG-IR-NMIBC With Thermally Gelling Mitomycin; Claims Supported By ENVISION And ATLAS Trials, Patent To Expire July 2044
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application no. 18...
07-15 20:02
